Clovis Oncology (CLVS) Short Interest Ratio & Short Volume → Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad) Free CLVS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Clovis Oncology Short Interest DataCurrent Short Volume28,490,000 sharesPrevious Short Volume28,020,000 sharesChange Vs. Previous Month+1.68%Dollar Volume Sold Short$9.40 millionShort Interest Ratio / Days to Cover6.9Last Record DateNovember 30, 2022Outstanding Shares144,955,000 sharesPercentage of Shares Shorted19.65%Today's Trading Volume1,155,888 sharesAverage Trading Volume8,875,886 sharesToday's Volume Vs. Average13% Short Selling Clovis Oncology ? Sign up to receive the latest short interest report for Clovis Oncology and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCLVS Short Interest Over TimeCLVS Days to Cover Over TimeCLVS Percentage of Float Shorted Over Time Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details Clovis Oncology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202228,490,000 shares $9.40 million +1.7%N/A6.9 $0.33 11/15/202228,020,000 shares $10.28 million -8.9%N/A7 $0.37 10/31/202230,770,000 shares $31.69 million -2.3%N/A10.5 $1.03 10/15/202231,490,000 shares $33.69 million -0.1%N/A10.1 $1.07 9/30/202231,510,000 shares $37.50 million -5.0%N/A7.7 $1.19 9/15/202233,160,000 shares $45.43 million +14.4%N/A3.9 $1.37 Get the Latest News and Ratings for CLVS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. 8/31/202228,990,000 shares $32.47 million -2.3%N/A2.3 $1.12 8/15/202229,660,000 shares $43.30 million +5.6%N/A2.4 $1.46 7/31/202228,080,000 shares $46.89 million -1.8%N/A2.1 $1.67 7/15/202228,580,000 shares $62.59 million -32.8%N/A2.1 $2.19 6/30/202242,550,000 shares $76.59 million +3.2%N/A3.1 $1.80 6/15/202241,250,000 shares $39.88 million +4.6%N/A2.6 $0.97 5/31/202239,450,000 shares $27.43 million +8.8%N/A3.3 $0.70 5/15/202236,270,000 shares $28.36 million +30.9%N/A3 $0.78 4/30/202227,710,000 shares $55.42 million -4.0%N/A2.3 $2.00 4/15/202228,850,000 shares $65.78 million +34.9%N/A2.6 $2.28 3/31/202221,380,000 shares $43.19 million -20.0%N/A2 $2.02 3/15/202226,730,000 shares $38.22 million -4.3%N/A5.5 $1.43 2/28/202227,940,000 shares $57.56 million +1.2%N/A6.5 $2.06 2/15/202227,610,000 shares $55.22 million -1.2%N/A6.3 $2.00 1/31/202227,950,000 shares $57.02 million +4.7%N/A6.5 $2.04 1/15/202226,700,000 shares $72.36 million +8.0%N/A0 $2.71 12/31/202124,720,000 shares $66.99 million -5.7%N/A7 $2.71 12/15/202126,200,000 shares $74.41 million -1.1%N/A8.2 $2.84 11/30/202126,480,000 shares $83.68 million +0.0%N/A8.3 $3.16 11/15/202126,470,000 shares $102.70 million -0.5%N/A8.7 $3.88 10/29/202126,600,000 shares $115.18 million +4.6%N/A9.7 $4.33 10/15/202125,420,000 shares $110.32 million -4.5%N/A9.1 $4.34 9/30/202126,610,000 shares $118.68 million +6.3%N/A7.9 $4.46 9/15/202125,030,000 shares $111.38 million -7.9%N/A6.7 $4.45 8/31/202127,170,000 shares $130.96 million -2.5%N/A6.3 $4.82 8/13/202127,870,000 shares $133.22 million -5.6%N/A5.1 $4.78 7/30/202129,520,000 shares $142.58 million +4.2%29.0%5.2 $4.83 7/15/202128,320,000 shares $146.13 million +4.1%27.8%4.9 $5.16 6/30/202127,200,000 shares $157.76 million -5.1%26.7%4.8 $5.80 6/15/202128,650,000 shares $165.31 million -7.0%28.1%5.1 $5.77 5/28/202130,810,000 shares $158.06 million -2.0%30.2%2.8 $5.13 5/14/202131,440,000 shares $176.69 million +3.2%N/A2.9 $5.62 4/30/202130,460,000 shares $183.37 million -3.8%N/A2.6 $6.02 4/15/202131,660,000 shares $197.88 million -1.8%N/A2.4 $6.25Wall Street Legend Issues New NVDA Warning (Ad)Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details CLVS Short Interest - Frequently Asked Questions What is Clovis Oncology's current short interest? Short interest is the volume of Clovis Oncology shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 28,490,000 shares of CLVS short. Learn More on Clovis Oncology's current short interest. What is a good short interest ratio for Clovis Oncology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLVS shares currently have a short interest ratio of 7.0. Learn More on Clovis Oncology's short interest ratio. Is Clovis Oncology's short interest increasing or decreasing? Clovis Oncology saw a increase in short interest during the month of November. As of November 30th, there was short interest totaling 28,490,000 shares, an increase of 1.7% from the previous total of 28,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Clovis Oncology's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Clovis Oncology: Molecular Templates, Inc. (1.15%), Fortress Biotech, Inc. (14.08%), Bolt Biotherapeutics, Inc. (8.20%), Monopar Therapeutics Inc. (2.29%), Purple Biotech Ltd. (0.88%), Imunon, Inc. (4.75%), Eterna Therapeutics Inc. (1.42%), Galera Therapeutics, Inc. (4.07%), RedHill Biopharma Ltd. (3.07%), Guardion Health Sciences, Inc. (13.71%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.93 billion), Suncor Energy Inc. ($3.50 billion), T. Rowe Price Group, Inc. ($2.29 billion), PG&E Co. ($1.73 billion), Coinbase Global, Inc. ($1.71 billion), Etsy, Inc. ($1.65 billion), Paramount Global ($1.54 billion), Lucid Group, Inc. ($1.50 billion), Old Dominion Freight Line, Inc. ($1.46 billion), and DICK'S Sporting Goods, Inc. ($1.41 billion). View all of the most shorted stocks. What does it mean to sell short Clovis Oncology stock? Short selling CLVS is an investing strategy that aims to generate trading profit from Clovis Oncology as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Clovis Oncology? A short squeeze for Clovis Oncology occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CLVS, which in turn drives the price of the stock up even further. How often is Clovis Oncology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLVS, twice per month. The most recent reporting period available is November, 30 2022. More Short Interest Resources from MarketBeat Related Companies: Molecular Templates Short Interest Fortress Biotech Short Interest Bolt Biotherapeutics Short Interest Monopar Therapeutics Short Interest Purple Biotech Short Interest Imunon Short Interest Eterna Therapeutics Short Interest Galera Therapeutics Short Interest RedHill Biopharma Short Interest Guardion Health Sciences Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CLVS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWall Street Legend Issues New NVDA WarningChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency